A fellowship position is available for a period of 3 years, tenable at Oxford University, on the project entitled “PersonaliseAF” to start before 1 July 2020. The successful applicant will be employed by the University on a Marie Sklodowska-Curie Innovative Training Network within the project “PersonalizeAF”, whose overall vision is to change the paradigm of classification and diagnosis of atrial fibrillation by delivering a precision medicine strategy based on the personalised characterisation of each atrial substrate and disease manifestation.
The closing date for applications is 12.00 noon on 24 February 2020.
For full details click here
Blinded In Silico Drug Trial Reveals the Minimum Set of Ion Channels for Torsades de Pointes Risk Assessment.
Zhou X, Qu Y, Passini E, Bueno-Orovio A, Liu Y, Vargas H, Rodriguez B. Frontiers in Pharmacology. 2020; 10:1643. doi: 10.3389/fphar.2019.01643.
Development, calibration, and validation of a novel human ventricular myocyte model in health, disease and drug block.
Tomek J, Bueno-Orovio A, Passini E, Zhou X, Mincholé A, Britton O, Bartolucci C, Severi S, Shrier A, Virag L, Varro A, Rodriguez B.
eLife. 2019 Dec 23; 8. pii: e48890. doi: 10.7554/eLife.48890.
High arrhythmic risk in antero-septal acute myocardial ischemia is explained by increased transmural reentry occurrence.
Martinez-Navarro H, Mincholé A, Bueno-Orovio A, Rodriguez B. Sci Rep. 2019 Nov 14;9(1):16803. doi: 10.1038/s41598-019-53221-2. PMID: 31728039.